VivoSeq
Other

Stem Cells

0

Pipeline Programs↗

7

Active Trials↗

3

Companies Involved↗

Stem Cells is an early-stage landscape with 0 programs across 3 companies. The most active players are Kyowa Kirin Co., Ltd., CAR-T (Shanghai) Biotechnology Co., Ltd., Guangdong ProCapZoom Biosciences Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

76/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

PreclinicalC

CAR-T (Shanghai) Biotechnology Co., Ltd.

0 programs

PreclinicalG

Guangdong ProCapZoom Biosciences Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

66

clinical trials

Completed32 · 48%
Unknown status16 · 24%
Terminated6 · 9%
Recruiting4 · 6%
Withdrawn4 · 6%
Active, not recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

66 trials

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06414889·4 enrolled
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
Recruiting·—·Phase 1·NCT05343572·90 enrolled
Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting
Recruiting·UUniversity of the Punjab·Phase 1·NCT05610878·24 enrolled
Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD
Recruiting·IIRCCS San Raffaele·Phase 2·NCT03055247·3 enrolled
Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage
Active, not recruiting·CClinical Center of Vojvodina·Phase 4·NCT07405840·60 enrolled
Venetoclax After TKI to Target Persisting Stem Cells in CML
Active, not recruiting·TThomas Ernst, PD Dr. med.·Phase 2·NCT05701215·10 enrolled
A Study of Stem Cells Lenses in the coGVHD Subjects
Not yet recruiting·GGuangdong ProCapZoom Biosciences Co., Ltd.·Phase 1·NCT06952114·6 enrolled
Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00005782·12 enrolled
Safety and Tolerability of Autologous Non-hematopoietic Peripheral Blood Stem Cells Therapy in Healthy Adult Volunteers.
Completed·AAbu Dhabi Stem Cells Center·Phase 1·NCT04645485·18 enrolled
Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft
Completed·UUniversity Hospital, Lille·N/A·NCT03280290·20 enrolled
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00082329·9 enrolled
Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars
Completed·HHeba Mohamed Saad Eldien·N/A·NCT03264573·40 enrolled
CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction
Completed·—·Phase 1·NCT00893360·31 enrolled
Stem Cells After Peripheral Mobilization and Harvest
Completed·AAndrews Research & Education Foundation·Phase 1·NCT03381599·10 enrolled
A Study of Stem Cells and Filgrastim
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001071·24 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)